Health knowledge made personal
Join this community!
› Share page:
Search posts:

Novel Inhibitors of Thymic Stromal Lymphopoietin (TSLP) for Cancer Therapy

Posted Apr 13 2011 8:00pm

Description of Invention:
With estimated overall costs in the U.S. in 2006 at $206.3 billion and WHO predictions of 15 million new cases globally by 2020, the overall economic cost of cancer is staggering. There remains a significant unmet need for therapies to control the spread (metastasis) of cancers to other organs in the body. Available for licensing are compositions and methods of using antagonists of thymic stromal lymphopoietin (TSLP) to prevent cancer progression and metastasis.

TSLP, an IL-7-like type 1 inflammatory cytokine that is often associated with the induction of Th2-type allergic responses in the lungs, is also expressed in cancers regulating their escape (1-3). The cancer-promoting activity of TSLP primarily required signaling through the TSLP receptor on CD4+ T cells, promoting Th2-skewed immune responses and production of immunosuppressive factors such as IL-10 and IL-13. Expression of TSLP therefore may be a useful prognostic marker and its targeting could have therapeutic potential. Inactivation of TSLP expression or its receptor signaling can effectively control cancer progression and metastasis (1).

  • In treatments to control cancer invasion and spreading
  • Cancer treatment that circumvents cancer-induced immune suppression
  • As a means to augment anti-tumor immune responses
  • For the development of prognostic markers for disease outcome in cancer patients

Arya Biragyn (NIA)
Warren J Leonard (NHLBI)

Patent Status:
HHS, Reference No. E-019-2011/0
US, Application No. 61/416,619 filed 23 Nov 2010

Relevant Publication:
  1. Olkhanud PB, Rochman Y, Bodogai M, Malchinkhuu E, Wejksza K, Xu M, Gress RE, Hesdorffer C, Leonard WJ, Biragyn A. Thymic stromal lymphopoietin is a key mediator of breast cancer progression. J Immunol. 2011;V:186, In Press.
  2. De Monte L, Reni M, Tassi E, Clavenna D, Papa I, Recalde H, Braga M, Di Carlo V, Doglioni C, Protti MP. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med. 2011 Mar 14;208(3):469-478. [ PubMed: 21339327 ]
  3. Pedroza-Gonzalez A, Xu K, Wu TC, Aspord C, Tindle S, Marches F, Gallegos M, Burton EC, Savino D, Hori T, Tanaka Y, Zurawski S, Zurawski G, Bover L, Liu YJ, Banchereau J, Palucka AK. Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation. J Exp Med. 2011 Mar 14;208(3):479-490. [ PubMed: 21339324 ]

Licensing Status:
Available for licensing.

Collaborative Research Opportunity:
The National Institute on Aging, Immunotherapeutics Unit, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize clinical application of TSLP in cancers. Please contact Nicole Guyton, Ph.D. at 301-435-3101 or for more information. Click here to view the NCI collaborative opportunity announcement.

Cancer - Therapeutics

For Licensing Information Please Contact:
Patrick McCue Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Phone: 301-496-7057
Fax: 301-402-0220

Ref No: 2249

Updated: 04/2011

Post a comment
Write a comment:

Related Searches